Press Releases

Liquidia Announces Closing of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C. , July 02, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the closing of its
Jul 02, 2020

Liquidia to Host Conference Call to Provide Update on Recent Announcements

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, will host a webcast and
Jun 29, 2020

Liquidia Announces Pricing of Public Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced the pricing of an
Jun 29, 2020

Liquidia Announces Proposed Offering of Common Stock

RESEARCH TRIANGLE PARK, N.C. , June 29, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT ®  technology, announced today that it has
Jun 29, 2020

Liquidia to Acquire RareGen, LLC, and Expand Presence in PAH

Acquisition Bolsters Liquidia’s Capabilities in Pulmonary Arterial Hypertension (PAH) and Commercial Readiness for LIQ861, if Approved Two New Directors, - Roger Jeffs , Ph.D. and Paul Manning , to Join Board Concurrent with Acquisition Close RESEARCH TRIANGLE PARK, N.C.
Jun 29, 2020

Liquidia to Present at the Jefferies Virtual Healthcare Conference

RESEARCH TRIANGLE PARK, N.C. , May 27, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced that Neal
May 27, 2020

Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer

RESEARCH TRIANGLE PARK, N.C. , May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies , Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products utilizing its proprietary PRINT ® technology, today announced the
May 18, 2020
Displaying 31 - 40 of 93